Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today?
Amylyx Pharmaceuticals (AMLX) surged 63% after reporting positive Phase 3 trial results for avexitide, with Stifel doubling its price target to $45. Iovance Biotherapeutics (IOVA) hit a 52-week high, driven by Q2 earnings and a price target increase from Mizuho. ONEOK (OKE) reached a 52-week high following strong Q2 earnings, raised 2026 guidance, and a new supply deal, with Morgan Stanley raising its target to $105.
How this was made
The 30-second read
Why it matters
Each company's new information provides a distinct catalyst for short‑term trading, with biotech trial data being especially high‑impact.
Market read
All three stocks experienced significant price moves on the day of the announcements, indicating high immediate market relevance.
What to watch
Potential regulatory delays for AMLX; IOVA's TIL therapy scale risks; OKE's contract depends on AI data‑center demand.
Background
The article aggregates fresh corporate developments for three U.S.-listed companies, each reporting material new data that moved their stocks to 52‑week highs.
Ticker impact
Phase 3 trial of avexitide showed 55% reduction in hypoglycemic events, prompting a 63% stock surge.
Further upside expected on FDA submission news.
Phase 3 results are material and rare for a small biotech, creating immediate trading catalyst.
Q2 earnings beat with 66% revenue growth and margin expansion, plus Mizuho raised price target.
Potential further upside if guidance remains strong.
Earnings beat and analyst upgrade provide a fresh catalyst for short-term moves.
Q2 earnings beat, raised 2026 EBITDA guidance by $250 M and announced a natural‑gas supply deal for a 1‑GW AI data‑center plant.
Likely continued upside as guidance is incorporated.
Guidance and contract are material new information for the utility sector.
Market effects
Biotech trial success may lift peer rare‑disease stocks; energy earnings boost utility sector sentiment.
U.S. markets see positive bias from earnings and trial news.
Limited to U.S. listed companies; no broader macro impact.
Counterpoint
Trial data may not translate to commercial success; earnings beat could be a one‑off.
Key entities
- CompanyAmylyx Pharmaceuticals
Biotech firm reporting Phase 3 trial results.
- CompanyIovance Biotherapeutics
Immunotherapy company reporting Q2 earnings beat.
- CompanyONEOK
Energy infrastructure firm reporting earnings beat and contract win.
